Edition:
United Kingdom

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,808.50GBp
8:47am BST
Change (% chg)

6.00 (+0.16%)
Prev Close
3,802.50
Open
3,826.00
Day's High
3,826.00
Day's Low
3,793.00
Volume
163,440
Avg. Vol
2,988,532
52-wk High
5,331.00
52-wk Low
3,603.50

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.53
Market Cap(Mil.): £34,319.05
Shares Outstanding(Mil.): 908.29
Dividend: 3.85
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.16 16.22
EPS (TTM): -- -- --
ROI: -- 14.31 15.23
ROE: -- 15.64 13.84

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

20 Sep 2017

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO, Sept 20 Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

20 Sep 2017

BRIEF-Shire and Shionogi announce positive topline results for Intuniv ​

* ‍SHIRE AND SHIONOGI ANNOUNCE POSITIVE TOPLINE RESULTS FOR INTUNIV EVALUATED IN PHASE 3 CLINICAL TRIAL IN ADULTS WITH ADHD​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

20 Sep 2017

BRIEF-Shire receives FDA fast track designation for SHP607

* SHIRE RECEIVES FDA FAST TRACK DESIGNATION FOR SHP607 FOR THE PREVENTION OF CHRONIC LUNG DISEASE IN EXTREMELY PREMATURE INFANTS

12 Sep 2017

Shire defends record as UBS cuts price target on staff satisfaction reviews

LONDON Shire is weathering a period a major change well, the company said on Tuesday, as analysts at UBS cut their price target on the stock in response to signs of falling staff satisfaction at the drugmaker.

29 Aug 2017

BRIEF-Shire announces collaboration with Microhealth to address needs of hemophilia A and B patients with inhibitors

* Shire announces collaboration with Microhealth to address unique needs of hemophilia A and B patients with inhibitors Source text for Eikon: Further company coverage:

25 Aug 2017

Shire's CFO resigns to join plant technology start-up

LONDON Pharmaceutical company Shire said its chief financial officer Jeff Poulton will stand down at the end of the year to join Indigo Ag, a Boston-based start-up that seeks to improve agricultural productivity.

21 Aug 2017

Shire's CFO resigns to join plant technology start-up

LONDON Pharmaceutical company Shire said its chief financial officer Jeff Poulton will stand down at the end of the year to join Indigo Ag, a Boston-based start-up that seeks to improve agricultural productivity.

21 Aug 2017

Shire's CFO resigns to join plant technology start-up

LONDON, Aug 21 Pharmaceutical company Shire said its chief financial officer Jeff Poulton will stand down at the end of the year to join Indigo Ag, a Boston-based start-up that seeks to improve agricultural productivity.

21 Aug 2017

BRIEF-Shire says CFO Jeff Poulton to leave at end of year

* Jeff Poulton, chief financial officer, will be leaving Shire at end of year to serve as CFO at Indigo AG Source text for Eikon: Further company coverage:

21 Aug 2017

Earnings vs. Estimates